Joel Navarro
Adult Health · Las Cruces, NMNPI 1275003154
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 40 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $708 and has fallen 78.7% since, to $151 in 2023.
Across 40 payments — averaging $26.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$195
- Amgen$160
- AstraZeneca$144
- Otsuka America Pharmaceutical, Inc.$110
- Vifor Pharma, Inc.$107
- Otsuka Pharmaceutical Development & Commercialization, Inc.$89
- plus $263 from 7 others
What the payments were for
- Food & beverage$1,068100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 3 | $195 |
| Amgen(2 entities) | 7 | $160 |
| AstraZeneca(2 entities) | 7 | $144 |
| Otsuka America Pharmaceutical, Inc. | 6 | $110 |
| Vifor Pharma, Inc. | 6 | $107 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $89 |
| Gilead | 1 | $62 |
| Akebia Therapeutics Inc | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $47 |
| Calliditas Therapeutics US Inc. | 1 | $39 |
| Fresenius USA Marketing, Inc. | 1 | $23 |
| GSK | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$111
How this compares
$1,068 in reported general payments places this provider in the 65th percentile of 52 adult health providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 17 | $169 |
| ClopidogrelClopidogrel Bisulfate | 11 | $79 |
| Levofloxacin | 19 | $55 |
Paid to pharmacies, not to this prescriber.
Other adult health in Las Cruces
- Kimberly MillerLas Cruces$3K
- Guadalupe TelfordLas Cruces$2K
- Elizabeth ReyesLas Cruces$1K
- Fatima McElveenLas Cruces$831
- Anthony VisconLas Cruces$568
- Salvador HernandezLas Cruces$482
- Cheryl LombardiLas Cruces$388
- Caroline McMillonLas Cruces$32
- Elizabeth HendricksLas Cruces$13
- Elizabeth EvansAlbuquerque$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.